ImmunityBio, Inc.
ImmunityBio, Inc. (IBRX) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · IBRX · as of Jun 8, 2026
Key Statistics
Explore ImmunityBio, Inc. Data
ibrx stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 5 · Buy rate: 100.0%
The IBRX analyst consensus is Buy, based on ratings from 5 Wall Street analysts over the past 3 months. The average 12-month price target is $13.00, representing +81.31% upside from the current price of $7.17.
Competitors & Peers
ibrx competitorsIBRX
AGIO
BEAM
COGT
DNLI
ETNBStock Performance
Full HistoryAbout ImmunityBio, Inc.
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to tre…
what is immunitybio, inc. · ibrx stock overview · immunitybio, inc. company profile · who is immunitybio, inc. ceo · ibrx NASDAQ · immunitybio, inc. headquarters · immunitybio, inc. business segments
About Stock Overview & Key Data
ImmunityBio, Inc. (IBRX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jul 28, 2015. As of the latest trading session, IBRX stock price is $7.17, with a market capitalization of $7.5B. The stock has returned +108.43% over the past 12 months and +262.12% year-to-date.
According to 5 Wall Street analysts, the consensus rating for ImmunityBio, Inc. stock is Buy, with an average 12-month price target of $13.00. In fiscal year 2025, ImmunityBio, Inc. reported revenue of $113.3M and net income of -$351.4M. For detailed data — including ImmunityBio, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, ImmunityBio, Inc. (IBRX) stock price is $7.17. The stock is traded on NASDAQ under the ticker symbol IBRX. The 52-week range is $1.95 – $12.43.